drugset
drugset / Trial / NCT02655419

Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)

NCT02655419 ↗

Phase 2 Completed 40 enrolled Pfizer Innovative Medicines Initiative · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Determine the PK and safety and tolerability of aztreonam-avibactam (ATM-AVI) in the treatment of hospitalized adults with cIAI

Timeline

Start
2016-05-19
Primary completion
2017-10-26
Completion
2017-10-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aztreonam Small molecule 3000 mg Other
Subject Aztreonam Small molecule 6000 mg Other
Subject avibactam Small molecule 820 mg Other
Subject avibactam Small molecule 1000 mg Other
Subject avibactam Small molecule 1640 mg Other
Subject avibactam Small molecule 2000 mg Other
Background Metronidazole Small molecule 500 mg Intravenous

Indications

No indication recorded.